AstraZeneca shares fell as results from a high-level study of a new cancer medicine raised concerns that the drug might not work as well as anticipated.
The drug helped patients with the most common form of lung cancer live longer without worsening compared with standard chemotherapy, the UK drugmaker said Monday. The stock fell as much as 6.2 per cent as investors were expecting a clearer statement on the trial’s success in terms of progression-free survival as well as how much longer patients lived overall.
